The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharma: CRISPR vectors. Buy the report here.

Smarter leaders trust GlobalData

Data Insights Innovation in Pharmaceuticals: CRISPR vectors

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Sanofi

Puretech Health Plc

CRISPR Therapeutics AG

View all

According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

CRISPR vectors is a key innovation area in genomics

CRISPR/Cas9 gene editing system works by cutting DNA precisely and allowing natural DNA repair processes to take over. The system consists of two parts, the Cas9 enzyme and a guide RNA. The delivery of CRISPR/Cas9 components into the cell fall into two broad categories, viral and non-viral.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 425+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of CRISPR vectors.

Key players in CRISPR vectors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to CRISPR vectors

CRISPR Therapeutics is the leading patent filer in CRISPR vectors. It is a gene editing company and focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells, ex vivo programs in immuno-oncology, in vivo programs targeting the liver, and additional in vivo programs targeting other organ systems, including muscle and lung.

In terms of application diversity, Illumina is the top company, followed by Keygene and Danaher.

By means of geographic reach, Application of Information and Communication Technologies (AICT) holds the top position. Intima Bioscience and Cibus Europe stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.